Osteoporosis is an international health and financial burden of ever increasing proportions. Current treatments limit the rate of bone resorption and reduce fracture risk, however they are often associated with significant and debilitating side effects. The most commonly used therapies also do not stimulate osteoblast activity 1,2,3. Much current research focus is aimed at the metabolic and epigenetic pathways involved in osteoporosis. MicroRNAs have been shown to play an important role in bone homeostasis and pathophysiological conditions of the musculoskeletal system. Up-regulation of specific microRNAs has been identified We have developed a 3D osteoporotic model from human bone marrow, without the use of scaffold. Magnetic nanoparticles are utilised to form spheroids, which provides a closer representation of the The results of initial monolayer and spheroid experiments will be presented. Optimisation of the osteoporotic bone marrow culture conditions, involving response to differentiation medias, analysis of adipose and bone markers and cell migration in spheroid culture will be displayed. Quantitative and qualitative results, including fluorescence microscopy and in cell western, assessing the monolayer and spheroid cultures will be presented. The development of a pseudo osteoporosis model from healthy bone marrow will also be discussed. This model will form a basis of future work on microRNA targeting. The development of improved therapies for osteoporosis is of great significance due to the predicted rise in incidence of the disease and associated fragility fractures. Targeted therapies, such as the manipulation of microRNA expression, offer the opportunity to increase osteoblastogenesis and decrease osteoclastogenesis, potentially without the associated side effects of older, systemic therapies. We believe our 3D human bone marrow derived osteoporotic model offers the closest relation to the
Osteoporosis is an international health and financial burden of ever increasing proportions. Current treatments limit the rate of bone resorption and reduce fracture risk, however they are often associated with significant and debilitating side effects. The most commonly used therapies also do not stimulate osteoblast activity. Much current research focus is aimed at the metabolic and epigenetic pathways involved in osteoporosis. MicroRNAs have been shown to play an important role in bone homeostasis and pathophysiological conditions of the musculoskeletal system. Upregulation of specific microRNAs has been identified in-vivo in osteoporotic patients. It is hypothesized that modulation of specific mircoRNA expression may have a key role in future targeted therapies of musculoskeletal diseases. The assessment and analysis of their potential therapeutic use in Osteoporosis is of great importance, due to the burden of the disease. We have developed a 3D osteoporotic model from human bone marrow, without the use of scaffold. Magnetic nanoparticles are utilised to form spheroids, which provides a closer representation of the The results of initial monolayer and spheroid experiments will be presented. Optimisation of the osteoporotic bone marrow culture conditions, involving response to differentiation medias, analysis of adipose and bone markers and cell migration in spheroid culture will be displayed. Quantitative and qualitative results, including fluorescence microscopy and in cell western, assessing the monolayer and spheroid cultures will be presented. The development of a pseudo osteoporosis model from healthy bone marrow will also be discussed. This model will form a basis of future work on miRNA targeting.
Ontogeny of long bone cross-sectional geometry has lasting effects on adult bone structure. Growth and development of bone is influenced by biological and mechanical factors but the importance of these factors is poorly understood. A study of prenatal, neonatal and infant development in a bone with simple loading patterns, may improve our understanding. Five vertebral columns aged between 6 months prenatal to 2.5 years postnatal, were analysed to quantify the changes in trabecular architecture before and after birth. Several measures were collected including trabecular: thickness, bone volume fraction, connectivity density, number, structure model index and anisotropy. The findings show that in the first year after birth there is a substantial loss of bone volume via decreasing trabecular thickness and number, which tends to increase after 1.2 years. This sequential pattern of development may be a functional response to the initial requirement for calcium mineral homeostasis before birth, followed by the need for trabecular architecture to adapt to mechanical loading after birth. Calcium is essential for growing neonates and therefore osteoclastic resorbtion is up regulated by increasing parathyroid hormone levels. This may account for the loss of bone between 0–1 year. At one year infants begin to walk bipedally, thus weight bearing and ground reaction forces increase. The stable bone volume and increase in organisation of trabecular architecture after one year may reflect increasing weight bearing and ground reaction forces. These findings suggest that nutritional requirements after birth may have a stronger influence on vertebral trabeculae architecture than learning to walk.